HAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human Health & Longevity and (ii) FoodTech & Bio-Farming, today announced that it has entered into a securities purchase agreement with a single healthc...
Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence
UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a marke t with an estimated size of ~$900 million annual ly , an d strengthens the foundation for broader international expansion HAIFA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable ce...
Two regenerative aesthetic and longevity products, with clinically validated ingredients , are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.